• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA approves no-comb lice treatment

Article

The Food and Drug Administration has approved prescription-strength lotion Sklice (Sanofi Pasteur) for the treatment of head lice in children ages 6 months and older.

Washington - The Food and Drug Administration has approved prescription-strength lotion Sklice (Sanofi Pasteur) for the treatment of head lice in children ages 6 months and older.

In clinical trials, a single, 10-minute application of Sklice, which contains the parasite-killing drug ivermectin 0.5 percent, eliminated lice from 75 percent of the 781 participants after two weeks, with no combing necessary, Time reports.

Less than 1 percent of the participants experienced side effects, which included conjunctivitis, eye irritation, dandruff, dry skin and a burning sensation.

Sanofi says Sklice should be available in the United States in a few months.

Go back to the Dermatology Times eNews newsletter.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.